This presentation was selected by the 13th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 13th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.

Statement of Need
Lung cancer is the deadliest form of cancer in the United States. Despite several decades of extensive research, the median survival in patients with advanced non–small cell lung cancer (NSCLC) is approximately 1 year. Most patients with early-stage disease will experience recurrence at a distant site, and 30%-60% of completely resected patients will die of their disease. Immunotherapy is a novel therapeutic modality that offers highly specific targeting of disseminated disease with minimal toxicity to normal tissues and represents a promising approach in the early and advanced disease settings. Many strategies that attempt to induce passive or active immunity against tumor cells in patients with NSCLC are being investigated, and several immunotherapeutic vaccines are in phase III clinical development. At the end of this activity, participants will be able to compare different strategies for immunotherapy in clinical development, and assess results from clinical trials that evaluate the safety and efficacy of protein-based, peptide-based, and whole tumor cell–based vaccines.  

Target Audience
This activity is intended for medical oncologists, physician assistants, and other healthcare professionals interested in the latest advances in immunotherapy for the treatment of patients with NSCLC.  

Educational Objectives
Upon completion of this activity, participants will be able to

1. Compare different immunotherapy strategies that are being investigated in the treatment of patients with NSCLC.
2. Evaluate results from clinical trials that evaluate the efficacy of protein- and peptide-based vaccines in the treatment of patients with NSCLC.
3. Assess the safety and efficacy of tumor cell vaccines in the treatment of patients with NSCLC.

Method of Participation
This symposium will use multiple methods of participation, including lectures, presentations, and panel discussions to engage attendees and enhance the learning process. 

Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category 1 credit for completing this program.



Certificate
The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

Acknowledgement of Commercial Support
The CBCE gratefully acknowledges the educational grant provided by EMD Serono, Inc.  

Americans with Disabilities Act
The CBCE fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the symposium registration desk. 

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or EMD Serono, Inc. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this activity.